Phase II study using a myeloablative lymphocyte depleting regimen of chemotherapy and intensive total body irradiation followed by infusion of tumor reactive lymphocytes and reconstitution with CD34+ stem cells in metastatic melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Antineoplastics; Cyclophosphamide; Fludarabine; Tumour infiltrating lymphocytes
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 18 Oct 2012 Biomarkers information updated
- 10 Apr 2009 Status changed from suspended to completed as reported by clinicaltrial.gov.
- 07 Mar 2008 Status changed from recruiting to suspended, according to ClinicalTrials.gov